| Igama | Eptifibatide |
| Inombolo yeCAS | 188627-80-7 |
| Ifomula yemolekyuli | I-C35H49N11O9S2 |
| Ubunzima bemolekyuli | 831.96 |
| Inombolo ye-EINECS | 641-366-7 |
| Ukuxinana | 1.60±0.1 g/cm3(Kuxelwe kwangaphambili) |
| Iimeko zokugcina | Ivalwe kwindawo eyomileyo, igcinwe kwisikhenkcisi, ngaphantsi kwe-15°C |
I-Eptifibatideacetatesalt;Eptifibatide,MPA-HAR-Gly-Asp-Trp-Pro-Cys-NH2,MPAHARGDWPC-NH2,>99%;MAP-LYS-GLY-ASP-TRP-PRO-CYS-NH2;INTEGRELIN;Eptifibatide;N6-(Aminoimi; nomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-La-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide;MPA-HAR-GLY-ASP-TRP-PRO-CYS-NH2(DISULFIDEBRIDGE,MPA1-CYS6).
I-Etifibatide (i-integrilin) yinoveli ye-polypeptide platelet glycoprotein IIb/IIIa receptor antagonist, ethintela ukuhlanganiswa kweplatelet kunye ne-thrombosis ngokuthintela indlela yokugqibela eqhelekileyo yokuhlanganiswa kweplatelet. Xa kuthelekiswa ne-monoclonal antibody abciximab, i-eptifibatide inamandla, i-directional ngakumbi kwaye ibophelela ngokuthe ngqo kwi-GPIIb / IIIa ngenxa yobukho be-amino acid enye yolondolozo-i-lysine yokubuyisela i-arginine. Ngoko ke, kufuneka ibe nefuthe elihle lonyango kunyango lokungenelela kwi-acute coronary syndrome. I-Platelet glycoprotein IIb/IIIa receptor antagonist iziyobisi ziye zaphuhliswa kakhulu, kwaye okwangoku kukho iintlobo ezi-3 zamalungiselelo anokusetyenziswa kwiikliniki kumazwe ngamazwe, abciximab, eptifibatide kunye ne- tirofiban. ). Kukho amava amancinci ekusebenziseni i-platelet glycoprotein GPIIb / IIIa i-receptor antagonists e-China, kwaye iziyobisi ezikhoyo nazo zincinci kakhulu. Linye kuphela ichiza, i tirofiban hydrochloride, ekhoyo kwimarike. Ngoko ke, iplatelet glycoprotein IIb entsha yaphuhliswa. /IIIa abachasi be-receptor bayafuneka. I-eptifibatide yasekhaya yimveliso yokulinganisa eveliswe yiChengdu Sino Biological Products Co., Ltd.
Ukuhlelwa kweAntiplatelet Aggregation Drugs
Amachiza okudibanisa i-Antiplatelet anokwahlulwa ngokungqongqo abe ngamacandelo amathathu: 1. Cyclooxygenase-1 (COX-1) inhibitors, njenge-aspirin. 2. Inhibit platelet aggregation eyenziwa yi-adenosine diphosphate (ADP), njenge-clopidogrel, i-prasugrel, i-cangrelor, i-ticagrelor, njl. ii-inhibitors, iinxalenye zekhemikhali ezisanda kwenziwa kunye nezicatshulwa ezisebenzayo kumayeza emveli aseTshayina.